Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma

Stock Information for Delcath Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.